ethyl 2-[5-(methoxycarbonyl)benzimidazol-2-yl]acetate | 668434-88-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: ethyl 2-[5-(methoxycarbonyl)benzimidazol-2-yl]acetate
• 英文别名: Ethyl 2-[5-(methoxycarbonyl)-benzimidazol-2-yl]acetate；methyl 2-(2-ethoxy-2-oxoethyl)-3H-benzimidazole-5-carboxylate
• CAS: 668434-88-6
• 化学式: C₁₃H₁₄N₂O₄
• 分子量: 262.265
• InChiKey: PCZSNBFWPAMYHK-UHFFFAOYSA-N

物化性质

• 熔点：
  113-114 °C
• 沸点：
  469.2±25.0 °C(Predicted)
• 密度：
  1.296±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  81.3
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  ethyl 2-[5-(methoxycarbonyl)benzimidazol-2-yl]acetate 、 2-氨基苯甲腈 在 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 为溶剂， 反应 5.0h， 以21%的产率得到methyl 2-(4-amino-2-oxo-1,2-dihydroquinolin-3-yl)-1H-benzo[d]imidazole-5-carboxylate
  参考文献：
  名称：

  Design, Structure−Activity Relationships and in Vivo Characterization of 4-Amino-3-benzimidazol-2-ylhydroquinolin-2-ones: A Novel Class of Receptor Tyrosine Kinase Inhibitors

  摘要：

  The inhibition of key receptor tyrosine kinases (RTKs) that are implicated in tumor vasculature formation and maintenance, as well as tumor progression and metastasis, has been a major focus in oncology research over the last several years. Many potent small molecule inhibitors of vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) kinases have been evaluated. More recently, compounds that act through the complex inhibition of multiple kinase targets have been reported and may exhibit improved clinical efficacy. We report herein a series of potent, orally efficacious 4-amino3-benzimidazol-2-ylhydroquinolin-2-one analogues as inhibitors of VEGF, PDGF, and fibroblast growth factor (FGF) receptor tyrosine kinases. Compounds in this class, such as 5 (TK1258), are reversible ATP-competitive inhibitors of VEGFR-2, FGFR-1, and PDGFR beta with IC50 values <0.1 mu M. On the basis of its favorable in vitro and in vivo properties, compound 5 was selected for clinical evaluation and is currently in phase I clinical trials.

  DOI：

  10.1021/jm800790t
• 作为产物：
  描述：

  3,4-二氨基苯甲酸甲酯 、 3-乙氧基-3-亚氨基丙酸乙酯盐酸盐 在 乙醇 、 二氯甲烷 、 Sodium sulfate-III 、 乙醚 作用下， 以 乙醇 为溶剂， 反应 16.0h， 以to yield the desired ethyl 2-[5-(methoxycarbonyl)-benzimidazol-2-yl]acetate as an off-white solid的产率得到ethyl 2-[5-(methoxycarbonyl)benzimidazol-2-yl]acetate
  参考文献：
  名称：

  Benzimidazole quinolinones and uses thereof

  摘要：

  治疗癌症的方法包括使用4-氨基-5-氟-3-(5-哌嗪-1-基-1H-苯并咪唑-2-基)喹啉-2(1H)-酮、4-氨基-5-氟-3-[5-(4-甲基-4-氧代哌嗪-1-基)-1H-苯并咪唑-2-基]喹啉-2(1H)-酮、其互变异构体、其药学上可接受的盐、其互变异构体的药学上可接受的盐或其混合物与癌细胞接触。

  公开号：

  US20050203101A1

文献信息

• Combination therapy with CHK1 inhibitors
  申请人：Gesner G. Thomas

  公开号：US20050256157A1

  公开（公告）日：2005-11-17

  Compounds of Structure I, and salts, tautomers, stereoisomers, and mixtures thereof may be used in methods of inhibiting checkpoint kinase 1 in subjects, in methods for inducing cell cycle progression, and in methods for increasing apoptosis in cells. Such compounds may be used to prepare pharmaceutical compositions and may be used in conjunction with DNA damaging agents.

  结构I的化合物及其盐类、互变异构体、立体异构体和混合物可用于抑制受试者中的检查点激酶1，用于诱导细胞周期进展的方法，以及用于增加细胞凋亡的方法。这些化合物可用于制备药物组合物，并且可以与DNA损伤剂联合使用。
• Inhibition of FGFR3 and treatment of multiple myeloma
  申请人：Cai Shaopei

  公开号：US20050261307A1

  公开（公告）日：2005-11-24

  Methods of inhibiting fibroblast growth factor receptor 3 and treating various conditions mediated by fibroblast growth factor receptor 3 are provided that include administering to a subject a compound of Structure I, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer. Compounds having the Structure I have the following structure where and have the variables described herein. Such compounds may be used to prepare medicaments for use in inhibiting fibroblast growth factor receptor 3 and for use in treating conditions mediated by fibroblast growth factor receptor 3 such as multiple myeloma.

  提供了抑制成纤维母细胞生长因子受体3并治疗由纤维母细胞生长因子受体3介导的各种疾病的方法，包括向受试者施用结构I的化合物，其药学上可接受的盐，其互变异构体，或其互变异构体的药学上可接受的盐。具有结构I的化合物具有以下结构，其中具有本文描述的变量。这些化合物可用于制备用于抑制纤维母细胞生长因子受体3和用于治疗由纤维母细胞生长因子受体3介导的疾病，如多发性骨髓瘤的药物。
• Synthesis and potent antimicrobial activity of some novel methyl or ethyl 1H-benzimidazole-5-carboxylates derivatives carrying amide or amidine groups
  作者：Seçkin Özden、Dilek Atabey、Sulhiye Yıldız、Hakan Göker

  DOI：10.1016/j.bmc.2004.12.025

  日期：2005.3.1

  and antifungal activities against S. aureus, methicillin resistant S. aureus (MRSA), S. faecalis, methicillin resistant S. epidermidis (MRSE), E. coli and C. albicans. The results showed that while all simple acetamides are essentially inactive, aromatic amides and amidines have potent antibacterial activities. Aromatic amidine derivatives 13 f-h exhibited the best inhibitory activity with 1.56-0.39

  合成了一系列在C-2位带有酰胺或am取代的甲基或苯基基团的苯并咪唑-5-羧酸烷基酯衍生物，并评估了其对金黄色葡萄球菌，耐甲氧西林金黄色葡萄球菌（MRSA）的抗菌和抗真菌活性，粪链球菌，耐甲氧西林的表皮葡萄球菌（MRSE），大肠杆菌和白色念珠菌。结果表明，尽管所有简单的乙酰胺基本上都没有活性，但芳族酰胺和am具有强大的抗菌活性。芳族am衍生物13 fh对MRSA和MRSE表现出最佳的抑制活性，其1.56-0.39 microg / mL MIC值。
• Benzimidazole quinolinones and uses thereof
  申请人：Chiron Corporation

  公开号：US20040092535A1

  公开（公告）日：2004-05-13

  Methods of inhibiting various enzymes and treating various conditions are provided that include administering to a subject a compound of Structure I or IB, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer. Compounds having the Structure I and IB have the following structures and have the variables described herein. Such compounds may be used to prepare medicaments for use in inhibiting various enzymes and for use in treating conditions mediated by such enzymes. 1

  提供了抑制各种酶和治疗各种疾病的方法，包括向受试者给予结构式I或IB的化合物、其药学上可接受的盐、其互变异构体或其药学上可接受的互变异构体盐。具有结构式I和IB的化合物具有以下结构，并具有此处描述的变量。这些化合物可用于制备药物，用于抑制各种酶的使用和用于治疗由这些酶介导的疾病。
• [EN] BENZIMIDAZOLE QUINOLINONES AND USES THEREOF<br/>[FR] QUINOLINONES DE BENZIMIDAZOLE ET LEURS UTILISATIONS
  申请人：CHIRON CORP

  公开号：WO2004018419A3

  公开（公告）日：2004-06-03